The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Novel Inhibitors of Cholesterol Degradation in Mycobacterium tuberculosis Reveal How the Bacterium’s Metabolism Is Constrained by the Intracellular Environment
Open accessAbstract
Mycobacterium tuberculosis (Mtb) relies on a specialized set of metabolic pathways to support growth in macrophages. By conducting an extensive, unbiased chemical screen to identify small molecules that inhibit Mtb metabolism within macrophages, we identified a significant number of novel compounds that limit Mtb growth in macrophages and in medium containing cholesterol as the principle carbon source. Based on this observation, we developed a chemical-rescue strategy to identify compounds that target metabolic enzymes involved in cholesterol metabolism. This approach identified two compounds that inhibit the HsaAB enzyme complex, which is required for complete degradation of the cholesterol A/B rings. The strategy also identified an inhibitor of PrpC, the 2-methylcitrate synthase, which is required for assimilation of cholesterol-derived propionyl-CoA into the TCA cycle. These chemical probes represent new classes of inhibitors with novel modes of action, and target metabolic pathways required to support growth of Mtb in its host cell. The screen also revealed a structurally-diverse set of compounds that target additional stage(s) of cholesterol utilization. Mutants resistant to this class of compounds are defective in the bacterial adenylate cyclase Rv1625/Cya. These data implicate cyclic-AMP (cAMP) in regulating cholesterol utilization in Mtb, and are consistent with published reports indicating that propionate metabolism is regulated by cAMP levels. Intriguingly, reversal of the cholesterol-dependent growth inhibition caused by this subset of compounds could be achieved by supplementing the media with acetate, but not with glucose, indicating that Mtb is subject to a unique form of metabolic constraint induced by the presence of cholesterol.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847
Drugs for bad bugs: confronting the challenges of antibacterial discovery
Payne, D. J., Gwynn, M. N., Holmes, D. J., & Pompliano, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2201 · Cited by 2,512
The spectrum of latent tuberculosis: rethinking the biology and intervention strategies
Barry, C. E., Boshoff, H. I., Dartois, V., Dick, T., Ehrt, S., Flynn, J., Schnappinger, D., Wilkinson, R. J., & Young, D. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2236 · Cited by 1,422
Transcriptional Adaptation of Mycobacterium tuberculosis within Macrophages
Schnappinger, D., Ehrt, S., Voskuil, M. I., Liu, Y., Mangan, J. A., Monahan, I. M., Dolganov, G., Efron, B., Butcher, P. D., Nathan, C., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030846 · Cited by 1,420
Self-citationMcKinney, J. D., zu Bentrup, K. H., Muñoz-Elías, E. J., Miczak, A., Chen, B., Chan, W.-T., Swenson, D., Sacchettini, J. C., Jacobs, W. R., & Russell, D. G. (2000) · Nature · doi:10.1038/35021074 · Cited by 1,360
Self-citationGenetic requirements for mycobacterial survival during infection
Sassetti, C. M., & Rubin, E. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2134250100 · Cited by 1,354
Mycobacterial persistence requires the utilization of host cholesterol
Pandey, A. K., & Sassetti, C. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711159105 · Cited by 1,064 · cited 1×
“Numerous studies have indicated that host-derived lipid (cholesterol and fatty acid) substrates and the metabolic pathways required for their utilization are important for Mtb replication during infection [11,16,23,24].”
BackgroundFranzblau, S. G., Witzig, R. S., McLaughlin, J. C., Torres, P., Madico, G., Hernandez, A., Degnan, M. T., Cook, M. B., Quenzer, V. K., Ferguson, R. M., et al. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.2.362-366.1998 · Cited by 964 · cited 2×
“To determine compound potency against Mtb in liquid culture an Alamar Blue reduction assay was used as described [22].”
MethodMycobacterium tuberculosis: here today, and here tomorrow
Russell, D. G. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35085034 · Cited by 789
Self-citationMuñoz-Elías, E. J., & McKinney, J. D. (2005) · Nature Medicine · doi:10.1038/nm1252 · Cited by 756
Cited by
Growth of Mycobacterium tuberculosis in vivo segregates with host macrophage metabolism and ontogeny
Huang, L., Nazarova, E. V., Tan, S., Liu, Y., & Russell, D. G. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20172020 · Cited by 569
Self-citationImmunometabolism at the interface between macrophages and pathogens
Russell, D. G., Huang, L., & VanderVen, B. C. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0124-9 · Cited by 460
Self-citationESX secretion systems: mycobacterial evolution to counter host immunity
Gröschel, M. I., Sayes, F., Simeone, R., Majlessi, L., & Brosch, R. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.131 · Cited by 382
New agents for the treatment of drug-resistant Mycobacterium tuberculosis
Hoagland, D. T., Liu, J., Lee, R. B., & Lee, R. E. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.026 · Cited by 328
Metabolic principles of persistence and pathogenicity in Mycobacterium tuberculosis
Ehrt, S., Schnappinger, D., & Rhee, K. Y. (2018) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0013-4 · Cited by 296
Pisu, D., Huang, L., Grenier, J. K., & Russell, D. G. (2020) · Cell Reports · doi:10.1016/j.celrep.2019.12.033 · Cited by 280
Self-citationThe Macrophage: A Disputed Fortress in the Battle against Mycobacterium tuberculosis
Queval, C. J., Brosch, R., & Simeone, R. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.02284 · Cited by 215
“In this perspective, it should be mentioned that remarkable progress has been made in developing new screening approaches that can simultaneously evaluate the antibacterial potency and the non-cytotoxic properties of small molecule inhibitors in the intracellular environment of Mtbinfected macrophages (Christophe et a…”
BackgroundInhibitors of Mycobacterium tuberculosis DosRST signaling and persistence
Zheng, H., Colvin, C. J., Johnson, B. K., Kirchhoff, P. D., Wilson, M., Jorgensen-Muga, K., Larsen, S. D., & Abramovitch, R. B. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2259 · Cited by 169
Self-citationStructure and function of adenylyl cyclases, key enzymes in cellular signaling
Khannpnavar, B., Mehta, V., Qi, C., & Korkhov, V. (2020) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2020.03.003 · Cited by 77
Dolan, S. K., Wijaya, A., Kohlstedt, M., Gläser, L., Brear, P., Silva-Rocha, R., Wittmann, C., & Welch, M. (2022) · mBio · doi:10.1128/mbio.02541-22 · Cited by 21
Dominguez, J., Mendes, A. I., Pacheco, A. R., Peixoto, M. J., Pedrosa, J., & Fraga, A. G. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1266261 · Cited by 4
“Cholesterol also contributes to the pool of metabolic building blocks, including acetyl-CoA, propionyl-CoA, succinyl-CoA, and pyruvate (Yam et al., 2009; Yang et al., 2009; Hu et al., 2010; Nesbitt et al., 2010; VanderVen et al., 2015), that are essential for mycolactone synthesis (Stinear et al.”
Metadata
- Authors
- VanderVen, B. C., Fahey, R. J., Lee, W., Liu, Y., Abramovitch, R. B., Memmott, C., Crowe, A. M., Eltis, L. D., Perola, E., Deininger, D. D., Wang, T., Locher, C. P., & Russell, D. G.
- Venue
- PLOS Pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-02-12
- Volume
- 11
- Issue
- 2
- Pages
- e1004679
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- OpenAlex
- W2022023246
- Cited by
- 263
- References
- 57
- FWCI
- 22.89
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.